More tools:Markets·Screener·Research·Chat

Agenus Inc. (AGEN) Financial Statements

Agenus Inc.
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001SDV370
XNAS · usd
7.43▼ 0.81 (-9.83%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close8.24
Day's Range7.42 – 8.18
52-Week Range2.71 – 8.85
Volume1.2M
Avg Volume1.3M
Share Statistics
Shares Outstanding
Employees81
ExchangeXNAS
Listed2000-02-04
Share count as of August 4, 2026
Loading Income Statement…
Key questions about Agenus Inc. (AGEN)
What is Agenus Inc.'s Market Cap?
Agenus Inc.'s Market Cap is $334.5M, based on as-reported figures from SEC (XBRL) filings.
What is Agenus Inc.'s Enterprise Value?
Agenus Inc.'s Enterprise Value is $345.8M, based on as-reported figures from SEC (XBRL) filings.
What is Agenus Inc.'s Trailing P/E?
Agenus Inc.'s Trailing P/E is 3.6×, based on as-reported figures from SEC (XBRL) filings.
What is Agenus Inc.'s Price / Sales?
Agenus Inc.'s Price / Sales is 2.5×, based on as-reported figures from SEC (XBRL) filings.
What is Agenus Inc.'s EV / Revenue?
Agenus Inc.'s EV / Revenue is 2.6×, based on as-reported figures from SEC (XBRL) filings.
What is Agenus Inc.'s EV / EBITDA?
Agenus Inc.'s EV / EBITDA is 9.3×, based on as-reported figures from SEC (XBRL) filings.
What is Agenus Inc.'s Revenue (TTM)?
Agenus Inc.'s Revenue (TTM) is $132.7M, based on as-reported figures from SEC (XBRL) filings.
What is Agenus Inc.'s Net Income (TTM)?
Agenus Inc.'s Net Income (TTM) is $91.7M, based on as-reported figures from SEC (XBRL) filings.
What is Agenus Inc.'s EBITDA?
Agenus Inc.'s EBITDA is $40.9M, based on as-reported figures from SEC (XBRL) filings.
What is Agenus Inc.'s Diluted EPS (TTM)?
Agenus Inc.'s Diluted EPS (TTM) is 2.04, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenues—
YoY growth+34.4%—+27.5%+20.4%
Operating expenses:
Cost of revenue—
Research and development—
General and administrative—
Fair value adjustments—
Total operating expenses———
% of revenue-67.3%———
Operating income (loss)—
% of revenue32.7%—42.1%-15.0%
Other income (expense):
Non-operating income (expense)—
MiNK Therapeutics, Inc. equity method investment fair value adjustment———
Interest expense, net—
Net income (loss)
% of revenue-1.6%—-31.0%211.4%
Dividends on Series A-1 convertible preferred stock—
Less: net loss attributable to non-controlling interest—
Net income (loss) attributable to Agenus Inc. common stockholders—
Basic——
Diluted——